10-KPeriod: FY2021

AbbVie Inc. Annual Report, Year Ended Dec 31, 2021

Filed February 18, 2022For Securities:ABBV

Summary

AbbVie Inc. reported robust performance in its 2021 10-K filing, with total net revenues reaching $56.2 billion, a significant increase driven largely by the full year inclusion of Allergan results post-acquisition and strong growth across its diverse product portfolio. The company highlighted growth in immunology, hematologic oncology, neuroscience, and aesthetics segments. The company's strategic focus remains on leveraging its diversified revenue base, expanding its pipeline through continued investment in R&D and strategic collaborations, and returning value to shareholders via dividends and debt reduction. Despite continued challenges from COVID-19 impacting new patient starts in certain areas, AbbVie demonstrated resilience, underscored by a substantial increase in operating cash flow and a significant increase in its quarterly cash dividend. Investors should note the substantial amortization of intangible assets related to the Allergan acquisition, which impacts reported earnings per share. The company is also navigating the upcoming loss of patent protection for Humira, with plans to offset this through growth in newer immunology products like Skyrizi and Rinvoq.

Financial Highlights

56 data points
Beta

Revenue

$56.20B

69.0% Gross Margin

Net Income

$11.54B

20.5% Net Margin

EPS (Diluted)

$6.45

Total Assets

$146.53B

Cash & Equivalents

$9.75B

Free Cash Flow

$21.99B

Financial Statements
Beta
Revenue$56.20B
Cost of Revenue$17.45B
Gross Profit$38.75B
SG&A Expenses$12.35B
Operating Expenses$38.27B
Operating Income$17.92B
Interest Expense$2.42B
Net Income$11.54B
EPS (Basic)$6.48
EPS (Diluted)$6.45
Shares Outstanding (Basic)1.77B
Shares Outstanding (Diluted)1.78B

Key Highlights

  • 1AbbVie's total net revenues reached $56.2 billion in 2021, a 22.7% increase over 2020, largely due to the full year impact of the Allergan acquisition and growth in key therapeutic areas.
  • 2Humira, despite facing biosimilar competition in Europe and a slight market share decrease in the US due to newer product launches, still contributed significantly with $20.7 billion in total net revenues.
  • 3Newer immunology products, Skyrizi and Rinvoq, demonstrated substantial growth, with net revenues increasing by 84.9% and over 100% respectively, indicating strong market adoption and pipeline success.
  • 4The Aesthetics and Neuroscience segments showed significant recovery and growth, driven by increased brand investment and a strong rebound from COVID-19 impacts, with Botox Cosmetic and Vraylar being key contributors.
  • 5AbbVie generated strong operating cash flow of $22.8 billion, supporting its strategic objectives, including continued investment in R&D, returning value to shareholders through dividends (an 8.5% increase in quarterly dividend declared), and debt reduction.
  • 6The company continues to invest heavily in R&D, with a pipeline of approximately 90 compounds, devices, or indications, indicating a commitment to future growth and innovation.
  • 7Despite robust financial performance, the company faces ongoing risks related to patent expirations (particularly for Humira), potential biosimilar competition, and regulatory changes in the pharmaceutical industry.

Frequently Asked Questions

AbbVie reported strong financial performance in 2021, with total net revenues reaching $56.2 billion, an increase of 22.7% compared to 2020. This growth was driven by the full year inclusion of Allergan's results and significant revenue increases across key therapeutic areas like immunology, hematologic oncology, neuroscience, and aesthetics. Operating earnings were $17.9 billion, and diluted earnings per share were $6.45, although the latter was impacted by substantial amortization of intangible assets from the Allergan acquisition.

AbbVie's strategy to mitigate the impact of Humira's patent expiration involves driving growth from its newer immunology products, Skyrizi and Rinvoq. These products have shown substantial year-over-year revenue increases and are gaining market share and expanding indications. The company also benefits from its diversified product portfolio across other therapeutic areas to offset potential revenue declines from Humira.

AbbVie is committed to returning value to shareholders through a combination of increasing cash dividends and share repurchases. In October 2021, the company's board declared an 8.5% increase in its quarterly cash dividend. Additionally, AbbVie continues to repurchase its own stock, with a remaining authorization of $2.5 billion as of December 31, 2021, and is focused on reducing debt.

AbbVie's key growth drivers include its immunology franchise with Skyrizi and Rinvoq, which are experiencing rapid adoption and indication expansion. In hematologic oncology, Imbruvica and Venclexta continue to perform well. The Aesthetics segment, bolstered by the Allergan acquisition, with products like Botox Cosmetic and the Juvederm Collection, is a significant contributor. The Neuroscience portfolio, including Botox Therapeutic and Vraylar, also shows strong growth.

AbbVie identifies several key risks, including the expiration or loss of patent protection for its products, particularly Humira, and the subsequent competition from generics and biosimilars. Other significant risks include the potential impact of public health outbreaks like COVID-19 on operations, challenges in research and development success, third-party intellectual property challenges, regulatory changes, pricing pressures, and the complexity of manufacturing biologic products. The company also notes risks associated with its debt obligations and the successful integration of acquired businesses.